Sanofi's isatuximab meets survival endpoint for third-line MM

Sanofi (Euronext:SAN; NASDAQ:SNY) said it will submit regulatory applications to FDA and EMA this half for isatuximab in relapsed or refractory multiple myeloma after the humanized IgG1 mAb against CD38

Read the full 304 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE